A prospective cohort study of ultra-rush subcutaneous immunotherapy in dust mite-induced allergic rhinitis

Key Points

• Ultra-rush subcutaneous immunotherapy significantly reduces allergic rhinitis symptoms over time, improving patients' quality of life.
• Participants experienced a notable 60% reduction in symptom scores within four weeks of starting treatment.
• Cohort study design tracked participants over several months, utilizing clinical assessments for symptom management.
• The findings indicate enhanced therapeutic strategies for managing dust mite-induced allergic rhinitis, calling for larger trials.